Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters

References

• Abdelmegeed M, Banerjee A, Yoo S, et al. (2012). Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. J Hepatol 57:860–866.
   PubMed Web of Science ®Google Scholar
• Abenavoli L, Milic N, Peta V, et al. (2014). Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol 20:16831–16840.
   PubMed Web of Science ®Google Scholar
• Aitken A, Morgan E. (2007). Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 35:1687–1693.
   PubMed Web of Science ®Google Scholar
• Aitken A, Richardson T, Morgan E. (2006). Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46:123–149.
   PubMed Web of Science ®Google Scholar
• Alberti K, Eckel R, Grundy S, et al. (2009). Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645.
   PubMed Web of Science ®Google Scholar
• Aljomah G, Baker SS, Liu W, et al. (2015). Induction of CYP2E1 in non-alcoholic fatty liver diseases. Exp Mol Pathol 99:677–681.
   PubMed Web of Science ®Google Scholar
• Anderson N, Borlak J. (2008). Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 60:311–357.
   PubMed Web of Science ®Google Scholar
• Angulo P, Keach J, Batts K, Lindor K. (1999). Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30:1356–1362.
   PubMed Web of Science ®Google Scholar
• Angulo P. (2002). Nonalcoholic fatty liver disease. N Engl J Med 346:1221–1231.
   PubMed Web of Science ®Google Scholar
• Argo C, Caldwell S. (2009). Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 13:511–531.
   PubMed Web of Science ®Google Scholar
• Aubert J, Begriche K, Knockaert L, et al. (2011). Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: Mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol 35:630–637.
   PubMed Web of Science ®Google Scholar
• Bae S, Kim J, Yang S, et al. (2006). Pharmacokinetics of oltipraz in rat models of diabetes mellitus induced by alloxan or streptozotocin. Life Sci 78:2287–2294.
   PubMed Web of Science ®Google Scholar
• Baldwin SJ, Clarke SE, Chenery RJ. (1999). Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 48:424–432.
   PubMed Web of Science ®Google Scholar
• Barnett C, Abbott R, Bailey C, et al. (1992). Cytochrome P-450-dependent mixed-function oxidase and glutathione S-transferase activities in spontaneous obesity-diabetes. Biochem Pharmacol 43:1868–1871.
   PubMed Web of Science ®Google Scholar
• Bazick J, Donithan M, Neuschwander-Tetri BA, et al. (2015). Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. Diabetes Care 38:1347–1355.
   PubMed Web of Science ®Google Scholar
• Bedossa P, Poitou C, Veyrie N, et al. (2012). Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56:1751–1759.
   PubMed Web of Science ®Google Scholar
• Bell M, Wang H, Chen H, et al. (2008). Consequences of lipid droplet coat protein downregulation in liver cells: Abnormal lipid droplet metabolism and induction of insulin resistance. Diabetes 57:2037–2045.
   PubMed Web of Science ®Google Scholar
• Bellentani S. (2017). The epidemiology of non-alcoholic fatty liver disease. Liver Int 37:81–84.
   PubMed Web of Science ®Google Scholar
• Browning J, Horton J. (2004). Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147–152.
   PubMed Web of Science ®Google Scholar
• Browning J, Szczepaniak L, Dobbins R, et al. (2004). Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 40:1387–1395.
   PubMed Web of Science ®Google Scholar
• Brunt E, Janney C, Di Bisceglie A, et al. (1999). Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467–2474.
   PubMed Web of Science ®Google Scholar
• Brunt E, Kleiner D, Wilson L, et al. (2011). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: Distinct clinicopathologic meanings. Hepatology 53:810–820.
   PubMed Web of Science ®Google Scholar
• Brunt E, Neuschwander-Tetri B, Oliver D, et al. (2004). Nonalcoholic steatohepatitis: Histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 35:1070–1082.
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Manzini P, D'antico S, et al. (2004). Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39:179–187.
   PubMed Web of Science ®Google Scholar
• Canet MJ, Hardwick RN, Lake AD, et al. (2014). Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models. Drug Metab Dispos 42:586–595.
   PubMed Web of Science ®Google Scholar
• Canet MJ, Merrell MD, Hardwick RN, et al. (2015). Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis. Drug Metab Dispos 43:829–835.
   PubMed Web of Science ®Google Scholar
• Caro A, Cederbaum A. (2004). Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol 44:27–42.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Gorski J, Asghar M, et al. (2003). Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 37:544–550.
   PubMed Web of Science ®Google Scholar
• Cholerton S, Daly A, Idle J. (1992). The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 13:434–439.
   PubMed Web of Science ®Google Scholar
• Clark J, Diehl A. (2003). Nonalcoholic fatty liver disease: An underrecognized cause of cryptogenic cirrhosis. JAMA 289:3000–3004.
   PubMed Web of Science ®Google Scholar
• Clarke JD, Dzierlenga AL, Nelson NR, et al. (2015). Mechanism of altered metformin distribution in nonalcoholic steatohepatitis. Diabetes 64:3305–3313.
   PubMed Web of Science ®Google Scholar
• Corey KE, Klebanoff MJ, Tramontano AC, et al. (2016). Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: A cost-effectiveness analysis. Dig Dis Sci 61:2108–2117.
   PubMed Web of Science ®Google Scholar
• Cotreau MM, Von Moltke LL, Greenblatt DJ. (2005). The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 44:33–60.
   PubMed Web of Science ®Google Scholar
• Cui Y, Wang Q, Yi X, Zhang X. (2016). Effects of fatty acids on CYP2A5 and Nrf2 expression in mouse primary hepatocytes. Biochem Genet 54:29–40.
   PubMed Web of Science ®Google Scholar
• Cusi K. (2016). Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: Current approaches and future directions. Diabetologia 59:1112–1120.
   PubMed Web of Science ®Google Scholar
• Diczfalusy U, Nylén H, Elander P, Bertilsson L. (2011). 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol 71:183–189.
   PubMed Web of Science ®Google Scholar
• Dixon J, Bhathal P, O'brien P. (2001). Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91–100.
   PubMed Web of Science ®Google Scholar
• Donato M, Lahoz A, Jiménez N, et al. (2006). Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos 34:1556–1562.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Petta S, Maglio C, et al. (2015). Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 61:506–514.
   PubMed Web of Science ®Google Scholar
• Dostalek M, Akhlaghi F, Puzanovova M. (2012a). Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet 51:481–499.
   PubMed Web of Science ®Google Scholar
• Dostalek M, Court M, Hazarika S, Akhlaghi F. (2011). Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos 39:448–455.
   PubMed Web of Science ®Google Scholar
• Dostalek M, Court M, Yan B, Akhlaghi F. (2011). Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol 163:937–947.
   PubMed Web of Science ®Google Scholar
• Dostalek M, Sam W, Paryani K, et al. (2012b). Diabetes mellitus reduces the clearance of atorvastatin lactone: Results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. Clin Pharmacokinet 51:591–606.
   PubMed Web of Science ®Google Scholar
• Dragovic S, Boerma J, Van Bergen L, et al. (2010). Role of human glutathione S-transferases in the inactivation of reactive metabolites of clozapine. Chem Res Toxicol 23:1467–1476.
   PubMed Web of Science ®Google Scholar
• Dzierlenga AL, Clarke JD, Hargraves TL, et al. (2015). Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis. J Pharmacol Exp Ther 352:462–470.
   PubMed Web of Science ®Google Scholar
• Eckel R, Alberti K, Grundy S, Zimmet P. (2010). The metabolic syndrome. Lancet 375:181–183.
   PubMed Web of Science ®Google Scholar
• Edginton A, Willmann S. (2008). Physiology-based simulations of a pathological condition: Prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet 47:743–752.
   PubMed Web of Science ®Google Scholar
• Elbekai R, Korashy H, El-Kadi A. (2004). The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab 5:157–167.
   PubMed Web of Science ®Google Scholar
• Elens L, Becker M, Haufroid V, et al. (2011). Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genom 21:861–866.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). (2016). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts 9:65–90.
   PubMed Web of Science ®Google Scholar
• Fabbrini E, Magkos F, Mohammed B, et al. (2009). Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 106:15430–15435.
   PubMed Web of Science ®Google Scholar
• Fazel Y, Koenig AB, Sayiner M, et al. (2016). Epidemiology and natural history of non-alcoholic fatty liver disease. Metab Clin Exp 65:1017–1025.
   PubMed Web of Science ®Google Scholar
• Ferslew BC, Johnston CK, Tsakalozou E, et al. (2015). Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. Clin Pharmacol Ther 97:419–427.
   PubMed Web of Science ®Google Scholar
• Finn RD, Henderson CJ, Scott CL, Wolf CR. (2009). Unsaturated fatty acid regulation of cytochrome P450 expression via a CAR-dependent pathway. Biochem J 417:43–54.
   PubMed Web of Science ®Google Scholar
• Fisher C, Jackson J, Lickteig A, et al. (2008). Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch Toxicol 82:959–964.
   PubMed Web of Science ®Google Scholar
• Fisher C, Lickteig A, Augustine L, et al. (2009). Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 37:2087–2094.
   PubMed Web of Science ®Google Scholar
• Fisher M, Yoon K, Vaughn M, et al. (2002). Flavin-containing monooxygenase activity in hepatocytes and microsomes: In vitro characterization and in vivo scaling of benzydamine clearance. Drug Metab Dispos 30:1087–1093.
   PubMed Web of Science ®Google Scholar
• Gao J, Zhou J, He XP, et al. (2016). Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: A bottom-up approach. Oncotarget 7:28612–28623.
   PubMed Web of Science ®Google Scholar
• George J, Liddle C, Murray M, et al. (1995). Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol 49:873–881.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang S-M, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236.
   PubMed Web of Science ®Google Scholar
• Godos J, Federico A, Dallio M, Scazzina F. (2017). Mediterranean diet and nonalcoholic fatty liver disease: Molecular mechanisms of protection. Int J Food Sci Nutr 68:18–27.
   PubMed Web of Science ®Google Scholar
• Greco D, Kotronen A, Westerbacka J, et al. (2008). Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 294:G1281–G1287.
   PubMed Web of Science ®Google Scholar
• Groop L. (1999). Insulin resistance: The fundamental trigger of type 2 diabetes. Diabetes Obes Metab 1:S1–S7.
   PubMed Web of Science ®Google Scholar
• Guengerich F, Macdonald T. (1990). Mechanisms of cytochrome P-450 catalysis. FASEB J 4:2453–2459.
   PubMed Web of Science ®Google Scholar
• Guengerich F, Munro A. (2013). Unusual cytochrome p450 enzymes and reactions. J Biol Chem 288:17065–17073.
   PubMed Web of Science ®Google Scholar
• Guengerich F. (1999). Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1–17.
   PubMed Web of Science ®Google Scholar
• Guengerich F. (2008). Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21:70–83.
   PubMed Web of Science ®Google Scholar
• Hanagama M, Inoue H, Kamiya M, et al. (2008). Gene expression on liver toxicity induced by administration of haloperidol in rats with severe fatty liver. Leg Med (Tokyo) 10:177–184.
   PubMedGoogle Scholar
• Hardwick R, Fisher C, Canet M, et al. (2010). Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 38:2293–2301.
   PubMed Web of Science ®Google Scholar
• Hardwick RN, Fisher CD, Street SM, et al. (2012). Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metab Dispos 40:450–460.
   PubMed Web of Science ®Google Scholar
• Harrison S, Torgerson S, Hayashi P. (2003). The natural history of nonalcoholic fatty liver disease: A clinical histopathological study. Am J Gastroenterol 98:2042–2047.
   PubMed Web of Science ®Google Scholar
• Hayes J, Flanagan J, Jowsey I. (2005). Glutathione transferases. Annu Rev Pharmacol Toxicol 45:51–88.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenom J 5:6–13.
   PubMed Web of Science ®Google Scholar
• Jaiswal A. (2004). Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med 36:1199–1207.
   PubMed Web of Science ®Google Scholar
• Jiang W, Wu N, Wang X, et al. (2015). Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep 5:8096.
   PubMed Web of Science ®Google Scholar
• Johns D. (1967). Human liver aldehyde oxidase: Differential inhibition of oxidation of charged and uncharged substrates. J Clin Invest 46:1492–1505.
   PubMed Web of Science ®Google Scholar
• Johnson T, Boussery K, Rowland-Yeo K, et al. (2010). A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 49:189–206.
   PubMed Web of Science ®Google Scholar
• Joshi-Barve S, Barve S, Amancherla K, et al. (2007). Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 46:823–830.
   PubMed Web of Science ®Google Scholar
• Jou J, Choi S, Diehl A. (2008). Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 28:370–379.
   PubMed Web of Science ®Google Scholar
• Jover R, Bort R, Gómez-Lechón M, Castell J. (2002). Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: Molecular mechanism and transcription factors involved. FASEB J 16:1799–1801.
   PubMed Web of Science ®Google Scholar
• Jover R, Moya M, Gómez-Lechón M. (2009). Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha. Curr Drug Metab 10:508–519.
   PubMed Web of Science ®Google Scholar
• Jump D, Botolin D, Wang Y, et al. (2005). Fatty acid regulation of hepatic gene transcription. J Nutr 135:2503–2506.
   PubMed Web of Science ®Google Scholar
• Jump D. (2008). N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol 19:242–247.
   PubMed Web of Science ®Google Scholar
• Kim Y, Lee A, Lee J, et al. (2005). Pharmacokinetics of theophylline in diabetes mellitus rats: Induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci 26:114–123.
   PubMed Web of Science ®Google Scholar
• Kirpich IA, Marsano LS, Mcclain CJ. (2015). Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem 48:923–930.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, et al. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313–1321.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Makhlouf HR. (2016). Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children. Clin Liver Dis 20:293–312.
   PubMed Web of Science ®Google Scholar
• Kolwankar D, Vuppalanchi R, Ethell B, et al. (2007). Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol 5:388–393.
   PubMed Web of Science ®Google Scholar
• Koren G, Cairns J, Chitayat D, et al. (2006). Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368:704.
   PubMed Web of Science ®Google Scholar
• Kulkarni NM, Malampati S, Mahat MY, et al. (2016). Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease. Drug Metab Pers Ther 31:165–171.
   PubMedGoogle Scholar
• Lee DY, Lee MG, Shin HS, Lee I. (2007). Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: Faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. J Pharm Pharm Sci 10:420–433.
   PubMed Web of Science ®Google Scholar
• Lennernäs H. (2003). Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141–1160.
   PubMed Web of Science ®Google Scholar
• Li H, Clarke JD, Dzierlenga AL, et al. (2017). In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice. J Biochem Mol Toxicol 31:e21840.
   Web of Science ®Google Scholar
• Li R, Guo G, Cao Y, et al. (2013). Expression of cytochrome P450 2A5 in a C57BL/6J mouse model of nonalcoholic fatty liver disease. Pharmacology 92:26–31.
   PubMed Web of Science ®Google Scholar
• Liu F, Song X, Yang D, et al. (2008). The far and distal enhancers in the CYP3A4 gene co-ordinate the proximal promoter in responding similarly to the pregnane X receptor but differentially to hepatocyte nuclear factor-4alpha. Biochem J 409:243–250.
   PubMed Web of Science ®Google Scholar
• Lucas D, Farez C, Bardou L, et al. (1998). Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol 12:553–558.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Brizi M, Morselli-Labate A, et al. (1999). Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107:450–455.
   PubMed Web of Science ®Google Scholar
• Martínez-Jiménez C, Gómez-Lechón M, Castell J, Jover R. (2005). Transcriptional regulation of the human hepatic CYP3A4: Identification of a new distal enhancer region responsive to CCAAT/enhancer-binding protein beta isoforms (liver activating protein and liver inhibitory protein). Mol Pharmacol 67:2088–2101.
   PubMed Web of Science ®Google Scholar
• Matteoni C, Younossi Z, Gramlich T, et al. (1999). Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 116:1413–1419.
   PubMed Web of Science ®Google Scholar
• Matzke G, Frye R, Early J, et al. (2000). Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 20:182–190.
   PubMed Web of Science ®Google Scholar
• Meech R, Mackenzie PI. (1997). Structure and function of uridine diphosphate glucuronosyltransferases. Clin Exp Pharmacol Physiol 24:907–915.
   PubMed Web of Science ®Google Scholar
• Merrell M, Cherrington N. (2011). Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev 43:317–334.
   PubMed Web of Science ®Google Scholar
• Michaut A, Moreau C, Robin M, Fromenty B. (2014). Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. Liver Int 34:e171–e179.
   PubMed Web of Science ®Google Scholar
• Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. (2003). Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425–461.
   PubMed Web of Science ®Google Scholar
• Mizuno N, Sugiyama Y. (2002). Drug transporters: Their role and importance in the selection and development of new drugs. Drug Metab Pharmacokinet 17:93–108.
   PubMedGoogle Scholar
• Mofrad P, Contos M, Haque M, et al. (2003). Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37:1286–1292.
   PubMed Web of Science ®Google Scholar
• Mohri T, Nakajima M, Fukami T, et al. (2010). Human CYP2E1 is regulated by miR-378. Biochem Pharmacol 79:1045–1052.
   PubMed Web of Science ®Google Scholar
• Morgan E. (2009). Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 85:434–438.
   PubMed Web of Science ®Google Scholar
• Naik A, Belič A, Zanger U, Rozman D. (2013). Molecular interactions between NAFLD and xenobiotic metabolism. Front Genet 4:1–14.
   Google Scholar
• Nakata K, Tanaka Y, Nakano T, et al. (2006). Nuclear receptor-mediated transcriptional regulation in phase I, II, and III xenobiotic metabolizing systems. Drug Metab Pharmacokinet 21:437–457.
   PubMed Web of Science ®Google Scholar
• Negishi M, Pedersen LG, Petrotchenko E, et al. (2001). Structure and function of sulfotransferases. Arch Biochem Biophys 390:149–157.
   PubMed Web of Science ®Google Scholar
• Pan Y, Gao W, Yu A. (2009). MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 37:2112–2117.
   PubMed Web of Science ®Google Scholar
• Persico M, Capasso M, Persico E, et al. (2007). Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 46:1009–1015.
   PubMed Web of Science ®Google Scholar
• Pettinelli P, Del Pozo T, Araya J, et al. (2009). Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: Correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim Biophys Acta 1792:1080–1086.
   PubMed Web of Science ®Google Scholar
• Ramadori G, Armbrust T. (2001). Cytokines in the liver. Eur J Gastroenterol Hepatol 13:777–784.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Charlotte F, Heurtier A, et al. (2005). Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128:1898–1906.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Giral P, Charlotte F, et al. (2000). Liver fibrosis in overweight patients. Gastroenterology 118:1117–1123.
   PubMed Web of Science ®Google Scholar
• Renton K. (2004). Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 5:235–243.
   PubMed Web of Science ®Google Scholar
• Rettie A, Meier G, Sadeque A. (1995). Prochiral sulfides as in vitro probes for multiple forms of the flavin-containing monooxygenase. Chem Biol Interact 96:3–15.
   PubMed Web of Science ®Google Scholar
• Rinella ME, Sanyal AJ. (2016). Management of NAFLD: A stage-based approach. Nat Rev Gastroenterol Hepatol 13:196–205.
   PubMed Web of Science ®Google Scholar
• Robertson G, Leclercq I, Farrell G. (2001). Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 281:G1135–G1139.
   PubMed Web of Science ®Google Scholar
• Roe A, Howard G, Blouin R, Snawder J. (1999). Characterization of cytochrome P450 and glutathione S-transferase activity and expression in male and female ob/ob mice. Int J Obes Relat Metab Disord 23:48–53.
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C, et al. (2008). Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461–1465.
   PubMed Web of Science ®Google Scholar
• Roth A, Looser R, Kaufmann M, Meyer U. (2008). Sterol regulatory element binding protein 1 interacts with pregnane X receptor and constitutive androstane receptor and represses their target genes. Pharmacogenet Genom 18:325–337.
   PubMed Web of Science ®Google Scholar
• Runge-Morris M, Kocarek T. (2005). Regulation of sulfotransferases by xenobiotic receptors. Curr Drug Metab 6:299–307.
   PubMed Web of Science ®Google Scholar
• Sanyal A, Campbell-Sargent C, Mirshahi F, et al. (2001). Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120:1183–1192.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Brunt EM, Kleiner DE, et al. (2011). Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54:344–353.
   PubMedGoogle Scholar
• Sanyal AJ, Friedman SL, Mccullough AJ, Dimick-Santos L. (2015). Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases – U.S. Food and Drug Administration Joint Workshop. Hepatology 61:1392–1405.
   PubMed Web of Science ®Google Scholar
• Sayiner M, Koenig A, Henry L, Younossi ZM. (2016). Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis 20:205–214.
   PubMed Web of Science ®Google Scholar
• Schmidt R, Baumann F, Hanschmann H, et al. (2001). Gender difference in ifosfamide metabolism by human liver microsomes. Eur J Drug Metab Pharmacokinet 26:193–200.
   PubMed Web of Science ®Google Scholar
• Shulman G. (2000). Cellular mechanisms of insulin resistance. J Clin Invest 106:171–176.
   PubMed Web of Science ®Google Scholar
• Sofia B, Segura-Aguilar J, Widersten M, et al. (1997). Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J 324:25–28.
   PubMed Web of Science ®Google Scholar
• Sookoian S, Pirola CJ. (2011). Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53:1883–1894.
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Mellemkjaer L, Jepsen P, et al. (2003). Risk of cancer in patients hospitalized with fatty liver: A Danish cohort study. J Clin Gastroenterol 36:356–359.
   PubMed Web of Science ®Google Scholar
• Sotaniemi EA, Pelkonen O, Arranto AJ, et al. (2002). Diabetes and elimination of antipyrine in man: An analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. Pharmacol Toxicol 90:155–160.
   PubMedGoogle Scholar
• Starley B, Calcagno C, Harrison S. (2010). Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 51:1820–1832.
   PubMed Web of Science ®Google Scholar
• Stepanova M, Hossain N, Afendy A, et al. (2010). Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease. Obes Surg 20:640–650.
   PubMed Web of Science ®Google Scholar
• Stevens J, Marsh S, Zaya M, et al. (2008). Developmental changes in human liver CYP2D6 expression. Drug Metab Dispos 36:1587–1593.
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kato Y, Tsuji A. (2006). Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition. J Control Release 116:238–246.
   PubMed Web of Science ®Google Scholar
• Tarantino G, Finelli C. (2013). What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J Gastroenterol 19:3375–3384.
   PubMed Web of Science ®Google Scholar
• Timsit Y, Negishi M. (2007). CAR and PXR: The xenobiotic-sensing receptors. Steroids 72:231–246.
   PubMed Web of Science ®Google Scholar
• Tiniakos D, Vos M, Brunt E. (2010). Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annu Rev Pathol 5:145–171.
   PubMed Web of Science ®Google Scholar
• Torisu T, Sato N, Yoshiga D, et al. (2007). The dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells 12:143–154.
   PubMed Web of Science ®Google Scholar
• Ueyama J, Wang D, Kondo T, et al. (2007). Toxicity of diazinon and its metabolites increases in diabetic rats. Toxicol Lett 170:229–237.
   PubMed Web of Science ®Google Scholar
• Vos B, Moreno C, Nagy N, et al. (2011). Lean non-alcoholic fatty liver disease (Lean-NAFLD): A major cause of cryptogenic liver disease. Acta Gastroenterol Belg 74:389–394.
   PubMed Web of Science ®Google Scholar
• Wang H, Tompkins LM. (2008). CYP2B6: New insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9:598–610.
   PubMed Web of Science ®Google Scholar
• Wang Z, Hall S, Maya J, et al. (2003). Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55:77–85.
   PubMed Web of Science ®Google Scholar
• Wells P, Mackenzie P, Chowdhury J, et al. (2004). Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab Dispos 32:281–290.
   PubMed Web of Science ®Google Scholar
• Weltman M, Farrell G, Liddle C. (1996). Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 111:1645–1653.
   PubMed Web of Science ®Google Scholar
• Werk A, Cascorbi I. (2014). Functional gene variants of CYP3A4. Clin Pharmacol Ther 96:340–348.
   PubMed Web of Science ®Google Scholar
• Wieckowska A, Feldstein AE. (2008). Diagnosis of nonalcoholic fatty liver disease: Invasive versus noninvasive. Semin Liver Dis 28:386–395.
   PubMed Web of Science ®Google Scholar
• Williams J, Hyland R, Jones B, et al. (2004). Drug–drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201–1208.
   PubMed Web of Science ®Google Scholar
• Wolbold R, Klein K, Burk O, et al. (2003). Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978–988.
   PubMed Web of Science ®Google Scholar
• Woolsey SJ, Beaton MD, Mansell SE, et al. (2016). A fibroblast growth factor 21-pregnane X receptor pathway downregulates hepatic CYP3A4 in nonalcoholic fatty liver disease. Mol Pharmacol 90:437–446.
   PubMed Web of Science ®Google Scholar
• Woolsey SJ, Mansell SE, Kim RB, et al. (2015). CYP3A activity and expression in nonalcoholic fatty liver disease. Drug Metab Dispos 43:1484–1490.
   PubMed Web of Science ®Google Scholar
• Yalcin E, More V, Neira K, et al. (2013). Downregulation of sulfotransferase expression and activity in diseased human livers. Drug Metab Dispos 41:1642–1650.
   PubMed Web of Science ®Google Scholar
• Yasui K, Hashimoto E, Komorizono Y, et al. (2011). Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 9:428–433. quiz e50.
   PubMed Web of Science ®Google Scholar
• Yoshioka Y, Hashimoto E, Yatsuji S, et al. (2004). Nonalcoholic steatohepatitis: Cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J Gastroenterol 39:1215–1218.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Baranova A, Ziegler K, et al. (2005). A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 42:665–674.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Blissett D, Blissett R, et al. (2016). The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64:1577–1586.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Negro F, et al. (2012). Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 91:319–327.
   PubMed Web of Science ®Google Scholar
• Zanger U, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–141.
   PubMed Web of Science ®Google Scholar
• Zein CO, Yerian LM, Gogate P, et al. (2011). Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial. Hepatology 54:1610–1619.
   PubMed Web of Science ®Google Scholar
• Zhang D. (2006). Mechanistic studies of the Nrf2–Keap1 signaling pathway. Drug Metab Rev 38:769–789.
   PubMed Web of Science ®Google Scholar
• Zhang W, Ramzan I, Murray M. (2007). Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. J Pharmacol Exp Ther 322:770–777.
   PubMed Web of Science ®Google Scholar